Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].
作者信息
Sinn K, Mosleh B, Steindl A, Zoechbauer-Mueller S, Dieckmann K, Widder J, Steiner E, Klepetko W, Hoetzenecker K, Laszlo V, Dome B, Klikovits T, Hoda M A
机构信息
Department of Thoracic Surgery, Medical University Vienna, Vienna.
Division of Oncology, Department of Medicine I, Medical University Vienna, Vienna.
出版信息
ESMO Open. 2022 Jun;7(3):100523. doi: 10.1016/j.esmoop.2022.100523. Epub 2022 Jun 10.
Abstract
摘要
相似文献
1
Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].《新辅助放化疗在手术治疗的Ⅲ期/N2期非小细胞肺癌中优于单纯化疗：一项回顾性单中心队列研究》勘误：[《ESMO Open》第7卷，第2期，2022年4月，100466]
ESMO Open. 2022 Jun;7(3):100523. doi: 10.1016/j.esmoop.2022.100523. Epub 2022 Jun 10.
2
Letter re: Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study.
ESMO Open. 2022 Oct;7(5):100535. doi: 10.1016/j.esmoop.2022.100535. Epub 2022 Sep 23.
3
Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191].《表皮生长因子受体（EGFR）突变的局部晚期非小细胞肺癌中吉非替尼诱导序贯放化疗：LOGIK0902/OLCSG0905 Ⅱ期研究》勘误：[《ESMO 开放》第 6 卷，第 4 期，2021 年 8 月，100191]
ESMO Open. 2022 Aug;7(4):100532. doi: 10.1016/j.esmoop.2022.100532. Epub 2022 Jul 6.
4
Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.对于ⅢA期（N2）非小细胞肺癌患者，在手术切除前接受新辅助化疗和/或放疗是否有生存获益：一项系统评价和Meta分析
Medicine (Baltimore). 2015 Jun;94(23):e879. doi: 10.1097/MD.0000000000000879.
5
Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis.比较可切除 IIIA/N2 期非小细胞肺癌的放化疗与化疗的获益：一项荟萃分析。
World J Surg Oncol. 2018 Jan 16;16(1):8. doi: 10.1186/s12957-018-1313-x.
6
Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).新辅助治疗后手术与 IIIA-N2 期非小细胞肺癌的根治性放化疗：西班牙放射肿瘤学会肺癌研究肿瘤学组的一项多机构研究。
Lung Cancer. 2018 Apr;118:119-127. doi: 10.1016/j.lungcan.2018.02.008. Epub 2018 Feb 14.
7
Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).新辅助治疗后手术治疗 IIIA-N2 期非小细胞肺癌的预后因素：西班牙放射肿瘤学会肺癌研究肿瘤学组的多机构研究。
Clin Transl Oncol. 2019 Jun;21(6):735-744. doi: 10.1007/s12094-018-1976-3. Epub 2018 Nov 14.
8
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.基于容积的18F-FDG PET/CT评估改善ⅢA-N2期非小细胞肺癌患者的预后预测
AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.
9
Corrigendum to 'Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study': [ESMO Open Volume 5, Issue 6, 2020, e000985].《ERBB2外显子16跳跃的临床意义：一项真实世界回顾性观察队列研究的分析》勘误：[《ESMO开放》第5卷，第6期，2020年，e000985]
ESMO Open. 2021 Feb;6(1):100052. doi: 10.1016/j.esmoop.2021.100052. Epub 2021 Jan 23.
10
Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.在 IIIA 期 N2 非小细胞肺癌的治疗中，与根治性放化疗相比，新辅助放化疗联合手术可改善生存结局。
Eur J Cardiothorac Surg. 2015 Nov;48(5):684-90; discussion 690. doi: 10.1093/ejcts/ezu504. Epub 2015 Jan 6.
Zotero 插件